Caricamento...
Macitentan in pulmonary arterial hypertension: The SERAPHIN trial
Major limitations of pulmonary arterial hypertension (PAH) drug trials include the small number of enrolled patients, short term follow up (12-16 weeks), and lack of morbidity and mortality primary endpoints. The recently published SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary...
Salvato in:
| Pubblicato in: | Glob Cardiol Sci Pract |
|---|---|
| Autore principale: | |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Bloomsbury Qatar Foundation Journals
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4220429/ https://ncbi.nlm.nih.gov/pubmed/25405173 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5339/gcsp.2014.20 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|